Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial

Peter A LeWitt; Robert A Hauser; Rajesh Pahwa; Stuart H Isaacson; Hubert H Fernandez; Mark Lew; Marie Saint-Hilaire; Emmanuelle Pourcher; Lydia Lopez-Manzanares; Cheryl Waters; Monika Rudzínska; Alexander Sedkov; Richard Batycky; Charles Oh

doi:10.1016/s1474-4422(18)30405-8

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet Neurology ◽

10.1016/s1474-4422(18)30405-8 ◽

2019 ◽

Vol 18 (2) ◽

pp. 145-154 ◽

Cited By ~ 29

Author(s):

Peter A LeWitt ◽

Robert A Hauser ◽

Rajesh Pahwa ◽

Stuart H Isaacson ◽

Hubert H Fernandez ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Motor Function ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Inhalation Powder

Download Full-text

Faculty Opinions recommendation of Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737065221.793569342 ◽

2020 ◽

Author(s):

Joseph Jankovic ◽

Arjun Tarakad

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of rasagiline monotherapy in Japanese patients with early Parkinson’s disease: A phase 3, randomized, double-blind, placebo-controlled, multicenter study

Journal of the Neurological Sciences ◽

10.1016/j.jns.2017.08.662 ◽

2017 ◽

Vol 381 ◽

pp. 231-232 ◽

Cited By ~ 1

Author(s):

N. Hattori ◽

A. Takeda ◽

S. Takeda ◽

A. Nishimura ◽

T. Kitagawa ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Multicenter Study ◽

Japanese Patients ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Early Parkinson’S Disease

Download Full-text

Efficacy and safety of istradefylline in moderate to severe Parkinson’s disease: A phase 3, multinational, randomized, double-blind, placebo-controlled trial (i-step study)

Journal of the Neurological Sciences ◽

10.1016/j.jns.2017.08.999 ◽

2017 ◽

Vol 381 ◽

pp. 351-352 ◽

Cited By ~ 1

Author(s):

S. Isaacson ◽

K. Eggert ◽

R. Kumar ◽

F. Stocchi ◽

A. Mori ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Controlled Trial ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Step Study

Download Full-text

A double-blind, placebo-controlled, dose-ranging study to investigate the safety and efficacy of CY 208-243 in patients with Parkinson's disease

Neurology ◽

10.1212/wnl.39.6.856 ◽

1989 ◽

Vol 39 (6) ◽

pp. 856-856 ◽

Cited By ~ 22

Author(s):

J. K.C. Tsui ◽

E. Ch. Wolters ◽

R. F. Peppard ◽

D. B. Calne

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Dose Ranging

Download Full-text

A phase IIb, randomised, double-blind, placebo-controlled, dose-ranging investigation of the safety and efficacy of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease

Parkinsonism & Related Disorders ◽

10.1016/j.parkreldis.2018.11.015 ◽

2019 ◽

Vol 61 ◽

pp. 88-93 ◽

Cited By ~ 9

Author(s):

Barry Snow ◽

Eoin Mulroy ◽

Arnold Bok ◽

Mark Simpson ◽

Andrew Smith ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Choroid Plexus ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Dose Ranging

Download Full-text

2.209 Long-term double-blind, placebo-controlled evaluation of the safety and efficacy of safinamide as an add-on to stable dopamine agonist therapy in patients with Parkinson's disease

Parkinsonism & Related Disorders ◽

10.1016/s1353-8020(08)70620-5 ◽

2007 ◽

Vol 13 ◽

pp. S99-S100 ◽

Cited By ~ 1

Author(s):

R. Anand ◽

V. Lucini ◽

R. Guiliani ◽

S. Rossetti

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Dopamine Agonist ◽

Agonist Therapy ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Dopamine Agonist Therapy ◽

Controlled Evaluation

Download Full-text

Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study

The Lancet Neurology ◽

10.1016/s1474-4422(19)30396-5 ◽

2020 ◽

Vol 19 (2) ◽

pp. 135-144 ◽

Cited By ~ 17

Author(s):

C Warren Olanow ◽

Stewart A Factor ◽

Alberto J Espay ◽

Robert A Hauser ◽

Holly A Shill ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients

Journal of the Neurological Sciences ◽

10.1016/j.jns.2011.05.021 ◽

2011 ◽

Vol 310 (1-2) ◽

pp. 248-250 ◽

Cited By ~ 23

Author(s):

Santiago Perez Lloret ◽

Gabriela Nano ◽

Andrea Carrosella ◽

Elkan Gamzu ◽

Marcelo Merello

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Pilot Study ◽

Short Term ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Multiple Doses

Download Full-text

Faculty Opinions recommendation of Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717995409.793474520 ◽

2013 ◽

Author(s):

Cynthia Comella

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Extended Release ◽

Immediate Release ◽

Motor Fluctuations ◽

Double Blind Trial ◽

Phase 3 ◽

Double Blind ◽

Blind Trial

Download Full-text

Faculty Opinions recommendation of Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8286956.8718054 ◽

2011 ◽

Author(s):

Irene Litvan ◽

Rita Simoes

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Depressive Symptoms ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text